In a short span of 15 years, we have recorded 100% growth in multiple years from USD 22 million in 2005 to USD 425 million in 2018.
- ISO 9001: 2008 (< 20 months of inception)
- WHO:GMP (< 24 months of inception)
- EUGMP (< 48 months of inception)
- USFDA (< 52 months of inception)
- Hamburg, Germany
- DSIR Recognition
- Korean FDA
- Department of Science & Technology, Govt. of India
- Department of Scientific and Industrial Research, Govt. of India
- Kenya MOH approved
- 120 US / EU / CEP / Korean / Canadian / Japanese DMFs
- 1500 dossiers
- 10 1st-in-India Generics
- 188 Indian & International Patents
Recognitions / Awards
- MSN Laboratories Wins National Intellectual Property(IP) Award 2016.
- MSN Laboratories Wins Pharmaexcil’s Patent Award 2015
- MSN Laboratories has been awarded TV5 Business Leader award 2015 in the Pharmaceutical (Medium Scale) category.
- MSN Laboratories Limited has been awarded CPhI India Award 2012 for "Innovation in Cost". It recognizes our contribution (1st-in-India generics of Bosentan, Lacosamide, Silodosin, etc. at very affordable prices) to Healthcare in India.
- Nominated as the Best Company in an Emerging Markets by Scrip Awards 2011
- PHARMEXCIL (Pharmaceutical Export Promotion Council) Outstanding Export Performer Award, 2009 & 2010
- FAPCCI Outstanding Export Performance Award in 2010
- ICICI-CNBC TV18-CRISIL Emerging India Award 2010 for pioneering 'systems focus' in the pharmaceutical sector.
- FAPCCI Excellence in R&D Award in 2008.
- Udyog Ratan Award.
- MSN has won the Customer Centric Business Partner Award from Abbott Healthcare Pvt. Ltd. for the year 2012.